AGP Executive Report
Last update: 2 hours agoCancer Care Breakthrough: GSK says partner Hansoh’s experimental small-cell lung cancer drug ris-rez hit its main survival goal in a late-stage China trial, with no new safety issues, as GSK pushes to expand beyond its core oncology areas. FDA Access Upgrade: The FDA approved a wearable, on-body injector version of Sanofi’s Sarclisa for multiple myeloma, aiming to cut infusion-center time and ease strain on oncology clinics. Medicaid Coverage Fight: A coalition of 25 states and D.C. sued over CMS Medicaid work requirements that could force many adults to prove work or training to keep coverage. Foodborne Illness Watch: Michigan’s cyclospora outbreak surged to 1,251 cases after a massive one-day jump, while the CDC also warned whooping cough remains active this summer, especially for unvaccinated infants. Public Health Emergency: The CDC scaled back FoodNet monitoring for foodborne illnesses, and cyclospora cases later spiked across multiple states. Policy & Health Costs: EPA proposed changes to reduce trucking compliance burdens tied to DEF deratements, promising major savings for operators. Health System Capacity: A study flags 50 million Americans living in counties without a radiation oncology clinic. Community Health & Safety: Residents urged preservation of Fort Oglethorpe’s historic Post hospital as property plans move forward.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
